A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.

@article{Farhat2011API,
  title={A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.},
  author={Fadi Sami Farhat and Sally N. Temraz and Joseph G. Kattan and Khaled Ibrahim and Nizar M A Bitar and Nadine G. Haddad and Rahif Jalloul and Hassan A. Hatoum and Ghazi Nsouli and Ali Shamseddine},
  journal={Clinical breast cancer},
  year={2011},
  volume={11 6},
  pages={384-9}
}
UNLABELLED We assessed the efficacy and safety of a liposomal cisplatin (lipoplatin) and vinorelbine combination in metastatic breast cancer (MBC). Thirty-five patients were treated. The objective response rate was 53.1% and the median survival time was 22 months. Grade 3/4 neutropenia was observed in 44% of cycles, and febrile neutropenia was seen in 4 patients (11.4%). No grade 3/4 nephrotoxicity or neuropathy was noted. This combination is effective and well tolerated in patients with MBC… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Liposomes as nanomedical devices

International journal of nanomedicine • 2015

Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2014
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Taxanes: a cornerstone of treatment for metastatic breast cancer

L. Schwartzberg
Commun Oncol • 2008
View 1 Excerpt

Breast cancer overview

L HBJardines, JH Doroshow, P Fisher
Cancer management: A multidisciplinary approach. 9th edition. New York (NY): CMP Healthcare • 2005
View 1 Excerpt

Similar Papers

Loading similar papers…